黄和化合物:神经退行性疾病治疗的有希望的途径
Teslime Özge Şahin1, Özge Cemali2, Merve Özdemir1
1Department of Nutrition and Dietetics, Faculty of Health Sciences, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkiye.
Turkish journal of biology = Turk biyoloji dergisi
|November 17, 2025
概括
黄胺在治疗神经退行性疾病 (如阿尔茨海默氏症和帕金森症) 中表现有前途,通过减少炎症和氧化压力. 提高它们的分娩效率可以提高它们作为补充疗法的有效性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 神经退行性疾病 (例如,阿尔茨海默氏症,帕金森病) 涉及逐渐的神经细胞损失,没有治疗方法.
- 常见的病理机制包括神经炎症,氧化应激,蛋白质聚合和线粒体功能障碍.
- 植物衍生的化合物黄类化合物因其抗炎和抗氧化特性而受到研究.
研究的目的:
- 审查黄类药物的神经保护机制.
- 评估它们在预防和治疗神经退行性疾病方面的潜力.
主要方法:
- 在Web of Science,PubMed和ScienceDirect数据库中进行文献搜索.
- 包括的研究:临床试验,RCT,体外/体内研究 (英语,最近的重点).
- 搜索词: "多", "黄", "阿尔茨海默病", "帕金森病", "亨廷顿病", "ALS".
主要成果:
- 特定的黄类化合物 (quercetin,myricetin,apigenin,EGCG) 调节信号通路,降低氧化应激,并防止蛋白质聚合.
- 这些化合物支持线粒体功能,并显示出减缓疾病进展的潜力.
- 治疗用途受到生物利用性差,稳定性低,代谢快速等因素的限制.
结论:
- 黄类药物提供多目标的神经保护,是有前途的天然药物.
- 新的输送系统和结构修改可以增强吸收和稳定性,提高临床疗效.
- 早期或补充服用黄类药物可能是安全有效的管理策略.
更多相关视频
相关概念视频
01:22Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
01:17Oxidation of Phenols to Quinones
4.5K
In the presence of oxidizing agents, phenols are oxidized to quinones. Quinones can be easily reduced back to phenols using mild reducing agents. The electron-donating hydroxyl group enhances the reactivity of the aromatic ring, enabling oxidation of the ring even in the absence of an α hydrogen.
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
4.5K
01:24Parkinson's Disease: Treatment
954
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
954
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
527
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
527